However, it is important to note that none of these studies compared the efficacy and tolerability of IT-administered PD-1/PD-L1 ICIs to conventional IV administration, which is needed to assess whether IT administration achieves similar anti-tumor efficacy with a lower incidence of irAEs. The gene discussed is CD274; the disease is neoplasm.